Combined Immunotherapy With Belatacept and BTLA Overexpression Attenuates Acute Rejection Following Kidney Transplantation

BACKGROUND: Costimulatory blockade provides new therapeutic opportunities for ensuring the long-term survival of kidney grafts. The adoption of the novel immunosuppressant Belatacept has been limited, partly due to concerns regarding higher rates and grades of acute rejection in clinical trials. In...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:Front Immunol
Autori principali: Zhang, Hengcheng, Wang, Zijie, Zhang, Jiayi, Gui, Zeping, Han, Zhijian, Tao, Jun, Chen, Hao, Sun, Li, Fei, Shuang, Yang, Haiwei, Tan, Ruoyun, Chandraker, Anil, Gu, Min
Natura: Artigo
Lingua:Inglês
Pubblicazione: Frontiers Media S.A. 2021
Soggetti:
Immunology
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC7959759/
https://ncbi.nlm.nih.gov/pubmed/33732243
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3389/fimmu.2021.618737
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi